Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27735637 | 0.81 | TSHR (0.46) | NPC1MAPTRAB9ATSHRHTT | |
| SCHEMBL127342 | 0.74 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1451262 | 0.71 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL87450 | 0.71 | CA1 (0.83) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1664013 | 0.71 | CA12 (0.75) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3659417 | 0.70 | DAO (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23202358 | 0.70 | DAO (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL128889 | 0.69 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3021302 | 0.69 | CA1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21440358 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-1263746-C | Pyridazinone derivatives | NIHON NOHYAKU CO LTD (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-6469003-B1 | COMPOUNDS HAVING CELL ADHESION INHIBITING ACTIVITY | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| CN-1323297-A | Pyridazinone derivatives | NIHON NOHYAKU CO LTD (JP) | 2001-11-21 | — | — | CN | disclosed |
| EP-1130015-A1 | PYRIDAZINONE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-4056544-A | Anthraquinone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | CA12 2239/4885CA1 2208/4885CA2 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.